Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

This study has been completed.
Elan Pharmaceuticals
Information provided by (Responsible Party):
Biogen Identifier:
First received: February 26, 2003
Last updated: June 14, 2016
Last verified: March 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2004
  Primary Completion Date: May 2004 (Final data collection date for primary outcome measure)